Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies
暂无分享,去创建一个
L. Sequist | J. Engelman | P. Fidias | A. Shaw | R. Heist | J. Temel | D. Gerber | A. Muzikansky | J. Gainor | M. Campo
[1] L. Sequist,et al. Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation‐positive non‐small cell lung cancer (NSCLC): Post‐hoc analyses of LUX‐Lung 3 (LL3) and LUX‐Lung 6 (LL6): 138PD , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] L. Sequist,et al. First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] Yih-Leong Chang,et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients , 2016, Oncotarget.
[4] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[5] Renato Martins,et al. Non-small cell lung cancer, version 1.2015. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] Yi-long Wu,et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[7] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Ladanyi,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[9] Yan Sun,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.
[10] J. Shih,et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. , 2012, The Lancet. Oncology.
[11] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[12] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.